Quan Joanne 4

What Happened
Joanne Quan, Chief Medical Officer of Mirum Pharmaceuticals (MIRM), converted 13,334 performance restricted stock units (RSUs) into common shares on March 15, 2026. Following the conversion, she sold 7,287 shares in an open-market transaction on March 16, 2026 at $91.98 per share, generating proceeds of approximately $670,243. The filing shows additional derivative-related activity associated with the conversion/settlement of the RSUs.

Key Details

• Transaction dates: conversion/exercise (derivative) on 2026-03-15; open-market sale on 2026-03-16.
• Open-market sale: 7,287 shares at $91.98 each; total proceeds ≈ $670,243.
• Conversion/exercise: 13,334 performance RSUs converted to common stock on 2026-03-15 (reported as derivative exercise/conversion).
• Footnotes: F1 = each performance RSU converts to one share; F2 = some shares were sold to cover tax withholding; F3 = vesting schedule — 2/3 vested 3/15/2026, 1/3 vests 3/15/2027.
• Shares owned after the transactions: not specified in the provided excerpt of the filing.
• Filing date: 2026-03-17; this appears to be filed timely relative to the reported transaction dates.

Context
This was primarily a conversion of performance RSUs followed by a partial sale. The sale appears to include shares sold in the open market and shares handled to cover tax withholding per footnote—common, routine actions when RSUs vest. This is a disposition (sale) rather than a purchase; such sales by executives are frequently for tax or diversification purposes and are not, by themselves, a clear signal of company outlook.